PET Imaging to Support Better Cancer Study

By Pharma Tech Outlook | Monday, February 04, 2019

According to cancer treatment and survivorship statistics, more than two hundred thousand women in the U.S. were estimated to develop breast cancer. Another research from the American Institute for Cancer Research is thinking of breast cancer as the most common cancer. Their study says that almost two million new cases of breast cancer came out in 2018. They have also presented a list of the most affected nations. As per their list, Belgium has the highest and Luxembourg has the second highest rate of breast cancer. These stats are awful and have propelled the researchers to pay more attention in this field.

In 2018, research in Perelman School of Medicine presented two important theses regarding this. This research thought about the advent of new technological devices to cope with this growing problem. In the first case, they used PET imaging and FluorThanatrace for the measurement of PARP-1 levels in cancer affected bodies. Previously, patients suffering from BRCA mutations and triple negative cancers were treated by destroying PARP-1 on which cancer cells depend on for their survival. But, there was no secured method to measure the level of PARP-1 expression. Indeed, this PET imaging will become a milestone in this field.

For the second study, the researchers used fluciclovine as an imaging agent to measure glutamine level. This imaging agent had previously gained the approval of FDA to be used for prostate cancer. As per a report presented in the Society of Nuclear Medicine and Molecular Imaging, it was used for detecting undetected lesions and to offer the necessary change in treatment management. But, these researchers thought to drag its periphery to different levels. They used it successfully to track the tumor glutamine level in case of triple negative breast cancer. This approach will help the treatment in manifold ways. It, on the one hand, will examine the glutamine level, and on the other hand, it will inform the physicians about the status of glutaminase inhibitors.

These tools play a vital role in the field of cancer study. It is helpful to the patients and the hospitals as well. Proper measurement of PRAP-1 expression and glutamine levels will facilitate the whole process of cancer treatment.

New Editions